Deciphering the molecular profile of plaques, memory decline and neuron loss in two mouse models for Alzheimer's disease by deep sequencing

Frontiers in Aging Neuroscience

Volumn 6, Issue APR, 2014, Pages

  Bouter, Yvonne ^a   Kacprowski, Tim ^b   Weissmann, Robert ^b   Dietrich, Katharina ^a   Borgers, Henning ^a   Brauß, Andreas ^a   Sperling, Christian ^b   Wirths, Oliver ^a   Albrecht, Mario ^b,c   Jensen, Lars R ^b   Kuss, Andreas W ^b   Bayer, Thomas A ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^c GRAZ UNIVERSITY OF TECHNOLOGY   (Austria)

Author keywords

5xFAD; Deep sequencing; Fear conditioning; Morris water maze; N truncated abeta; Spatial reference memory; Tg4 42; Transcriptome

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; MESSENGER RNA;

AGED; ALZHEIMER DISEASE; AMNESIA; AMYLOID PLAQUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL LOSS; CONDITIONING; CONTROLLED STUDY; FEAR; GENE EXPRESSION; GENE SEQUENCE; MORRIS WATER MAZE TEST; MOUSE; MOUSE MODEL; NERVE CELL; NONHUMAN; PROTEIN AGGREGATION; REFERENCE MEMORY; SPATIAL MEMORY;

EID: 84901378800     PISSN: None     EISSN: 16634365     Source Type: Journal    
DOI: 10.3389/fnagi.2014.00075     Document Type: Article

References (120)

1. Akiyama, H., Barger, S., Barnum, S., Bradt, B., Bauer, J., Cole, G. M., et al. (2000). Inflammation and Alzheimer's disease. Neurobiol. Aging 21, 383-421. doi:10.1016/S0197-4580(00)00124-X
2. Altar, A. C., Vawter, M. P., and Ginsberg, S. D. (2009). Target identification for CNS diseases by transcriptional profiling. Neuropsychopharmacology 34, 18-54. doi:10.1038/npp.2008.172
3. Alzheimer's Association. (2012). 2012 Alzheimer's disease facts and figures. Alzheimers Dement. 8, 131-168. doi:10.1016/j.jalz.2012.02.001
4. Anders, S., and Huber, W. (2010). Differential expression analysis for sequence count data. Genome Biol. 11, R106. doi:10.1186/gb-2010-11-10-r106
5. Arnaud, L., Robakis, N. K., and Figueiredo-Pereira, M. E. (2006). It may take inflammation, phosphorylation and ubiquitination to 'tangle' in Alzheimer's disease. Neurodegener. Dis. 3, 313-319. doi:10.1159/000095638
6. Ashburner, M., Ball, C. A., Blake, J. A., Botstein, D., Butler, H., Cherry, J. M., et al. (2000). Gene ontology: tool for the unification of biology. The gene ontology consortium. Nat. Genet. 25, 25-29. doi:10.1038/75556
7. Bast, T., Zhang, W.-N., and Feldon, J. (2003). Dorsal hippocampus and classical fear conditioning to tone and context in rats: effects of local NMDA-receptor blockade and stimulation. Hippocampus 13, 657-675. doi:10.1002/hipo.10115
8. Benilova, I., Karran, E., and DeStrooper, B. (2012). The toxic Aß oligomer and Alzheimer's disease: an emperor in need of clothes. Nat. Neurosci. 15, 349-357. doi:10.1038/nn.3028
9. Bertram, L., and Tanzi, R. E. (2001). Dancing in the dark? The status of late-onsetalzheimer's disease genetics. J. Mol. Neurosci. 17, 127-136. doi:10.1385/JMN:17:2:127
10. Blennow, K., deLeon, M. J., and Zetterberg, H. (2006). Alzheimer's disease. Lancet 368, 387-403. doi:10.1016/S0140-6736(06)69113-7
11. Bossers, K., Wirz, K. T. S., Meerhoff, G. F., Essing, A. H. W., van Dongen, J. W., Houba, P., et al. (2010). Concerted changes in transcripts in the prefrontal cortex precede neuropathology in Alzheimer's disease. Brain 133, 3699-3723. doi:10.1093/brain/awq258
12. Bouter, Y., Dietrich, K., Wittnam, J. L., Rezaei-Ghaleh, N., Pillot, T., Papot-Couturier, S., et al. (2013). N-truncated amyloid ß (Aß) 4-42 forms stable aggregates and induces acute and long-lasting behavioral deficits. Acta Neuropathol. 126, 189-205. doi:10.1007/s00401-013-1129-2
13. Breyhan, H., Wirths, O., Duan, K., Marcello, A., Rettig, J., and Bayer, T. A. (2009). APP/PS1KI bigenic mice develop early synaptic deficits and hippocampus atrophy. Acta Neuropathol. 117, 677-685. doi:10.1007/s00401-009-0539-7
14. Carrasquillo, M. M., Belbin, O., Hunter, T. A., Ma, L., Bisceglio, G. D., Zou, F., et al. (2010). Replication of CLU, CR1, and PICALM associations with Alzheimer disease. Arch. Neurol. 67, 961-964. doi:10.1001/archneurol.2010.147
15. Carrette, O., Demalte, I., Scherl, A., Yalkinoglu, O., Corthals, G., Burkhard, P., et al. (2003). A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease. Proteomics 3, 1486-1494. doi:10.1002/pmic.200300470
16. Casas, C., Sergeant, N., Itier, J.-M., Blanchard, V., Wirths, O., van der Kolk, N., et al. (2004). Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Abeta42 accumulation in a novel Alzheimer transgenic model. Am. J. Pathol. 165, 1289-1300. doi:10.1016/S0002-9440(10)63388-3
17. Cataldo, A. M., Barnett, J. L., Berman, S. A., Li, J., Quarless, S., Bursztajn, S., et al. (1995). Gene expression and cellular content of cathepsin D in Alzheimer's disease brain: evidence for early up-regulation of the endosomal-lysosomal system. Neuron 14, 671-680. doi:10.1016/0896-6273(95)90324-0
18. Chen, G., Chen, K. S., Knox, J., Inglis, J., Bernard, A., Martin, S. J., et al. (2000). A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Nature 408, 975-979. doi:10.1038/35050103
19. Cheng, L., Quek, C. Y. J., Sun, X., Bellingham, S. A., and Hill, A. F. (2013). The detection of microRNA associated with Alzheimer's disease in biological fluids using next-generation sequencing technologies. Front. Genet. 4:150. doi:10.3389/fgene.2013.00150
20. Choi, J. W., Kang, S. M., Lee, Y., Hong, S. H., Sanek, N. A., Young, W. S., et al. (2013). MicroRNA profiling in the mouse hypothalamus reveals oxytocin-regulating microRNA. J. Neurochem. 126, 331-337. doi:10.1111/jnc.12308
21. Christensen, D. Z., Bayer, T. A., and Wirths, O. (2010). Intracellular Aß triggers neuron loss in the cholinergic system of the APP/PS1KI mouse model of Alzheimer's disease. Neurobiol. Aging 31, 1153-1163. doi:10.1016/j.neurobiolaging.2008.07.022
22. Christensen, D. Z., Kraus, S. L., Flohr, A., Cotel, M.-C., Wirths, O., and Bayer, T. A. (2008). Transient intraneuronal A beta rather than extracellular plaque pathology correlates with neuron loss in the frontal cortex of APP/PS1KI mice. Acta Neuropathol. 116, 647-655. doi:10.1007/s00401-008-0451-6
23. Cocco, C., D'Amato, F., Noli, B., Ledda, A., Brancia, C., Bongioanni, P., et al. (2010). Distribution of VGF peptides in the human cortex and their selective changes in Parkinson's and Alzheimer's diseases. J. Anat. 217, 683-693. doi:10.1111/j.1469-7580.2010.01309.x
24. Couillard-Despres, S., Winner, B., Schaubeck, S., Aigner, R., Vroemen, M., Weidner, N., et al. (2005). Doublecortin expression levels in adult brain reflect neurogenesis. Eur. J. Neurosci. 21, 1-14. doi:10.1111/j.1460-9568.2004.03813.x
25. Courtney, E., Kornfeld, S., Janitz, K., and Janitz, M. (2010). Transcriptome profiling in neurodegenerative disease. J. Neurosci. Methods 193, 189-202. doi:10.1016/j.jneumeth.2010.08.018
26. Cruz, J. C., and Tsai, L.-H. (2004). Cdk5 deregulation in the pathogenesis of Alzheimer's disease. Trends Mol. Med. 10, 452-458. doi:10.1016/j.molmed.2004.07.001
27. Delacourte, A. (1990). General and dramatic glial reaction in Alzheimer brains. Neurology 40, 33-37. doi:10.1212/WNL.40.1.33
28. Dickey, C. A., Loring, J. F., Montgomery, J., Gordon, M. N., Eastman, P. S., and Morgan, D. (2003). Selectively reduced expression of synaptic plasticity-related genes in amyloid precursor protein + presenilin-1 transgenic mice. J. Neurosci. 23, 5219-5226.
29. España, J., Giménez-Llort, L., Valero, J., Miñano, A., Rábano, A., Rodriguez-Alvarez, J., et al. (2010). Intraneuronal beta-amyloid accumulation in the amygdala enhances fear and anxiety in Alzheimer's disease transgenic mice. Biol. Psychiatry 67, 513-521. doi:10.1016/j.biopsych.2009.06.015
30. Farris, W., Mansourian, S., Chang, Y., Lindsley, L., Eckman, E. A., Frosch, M. P., et al. (2003). Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc. Natl. Acad. Sci. U.S.A. 100, 4162-4167. doi:10.1073/pnas.0230450100
31. George, A. J., Gordon, L., Beissbarth, T., Koukoulas, I., Holsinger, R. M., Perreau, V., et al. (2010). A serial analysis of gene expression profile of the Alzheimer's disease Tg2576 mouse model. Neurotox. Res. 17, 360-379. doi:10.1007/s12640-009-9112-3
32. Glaser, S., Schaft, J., Lubitz, S., Vintersten, K., van der Hoeven, F., Tufteland, K. R., et al. (2006). Multiple epigenetic maintenance factors implicated by the loss of Mll2 in mouse development. Development 133, 1423-1432. doi:10.1242/dev.02302
33. Haass, C., and Selkoe, D. J. (2007). Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell Biol. 8, 101-112. doi:10.1038/nrm2101
34. Hardy, J., and Allsop, D. (1991). Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol. Sci. 12, 383-388. doi:10.1016/0165-6147(91)90609-V
35. Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., et al. (2009). Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat. Genet. 41, 1088-1093. doi:10.1038/ng.440
36. Haughey, N. J., Liu, D., Nath, A., Borchard, A. C., and Mattson, M. P. (2002a). Disruption of neurogenesis in the subventricular zone of adult mice, and in human cortical neuronal precursor cells in culture, by amyloid beta-peptide: implications for the pathogenesis of Alzheimer's disease. Neuromolecular Med. 1, 125-135. doi:10.1385/NMM:1:2:125
37. Haughey, N. J., Nath, A., Chan, S. L., Borchard, A. C., Rao, M. S., and Mattson, M. P. (2002b). Disruption of neurogenesis by amyloid beta-peptide, and perturbed neural progenitor cell homeostasis, in models of Alzheimer's disease. J. Neurochem. 83, 1509-1524. doi:10.1046/j.1471-4159.2002.01267.x
38. Haupt, C., Leppert, J., Rönicke, R., Meinhardt, J., Yadav, J. K., Ramachandran, R., et al. (2012). Structural basis of ß-amyloid-dependent synaptic dysfunctions. Angew. Chem. Int. Ed. Engl. 51, 1576-1579. doi:10.1002/anie.201105638
39. Hillmann, A., Hahn, S., Schilling, S., Hoffmann, T., Demuth, H.-U., Bulic, B., et al. (2012). No improvement after chronic ibuprofen treatment in the 5XFAD mouse model of Alzheimer's disease. Neurobiol. Aging 33, .e39-.e50. doi:10.1016/j.neurobiolaging.2011.08.006
40. Hirokawa, N., Niwa, S., and Tanaka, Y. (2010). Molecular motors in neurons: transport mechanisms and roles in brain function, development, and disease. Neuron 68, 610-638. doi:10.1016/j.neuron.2010.09.039
41. Hirokawa, N., Noda, Y., Tanaka, Y., and Niwa, S. (2009). Kinesin superfamily motor proteins and intracellular transport. Nat. Rev. Mol. Cell Biol. 10, 682-696. doi:10.1038/nrm2774
42. Hook, V. Y., Kindy, M., Reinheckel, T., Peters, C., and Hook, G. (2009). Genetic cathepsin B deficiency reduces beta-amyloid in transgenic mice expressing human wild-type amyloid precursor protein. Biochem. Biophys. Res. Commun. 386, 284-288. doi:10.1016/j.bbrc.2009.05.131
43. Jaffrey, S. R., Benfenati, F., Snowman, A. M., Czernik, A. J., and Snyder, S. H. (2002). Neuronal nitric-oxide synthase localization mediated by a ternary complex with synapsin and CAPON. Proc. Natl. Acad. Sci. U.S.A. 99, 3199-3204. doi:10.1073/pnas.261705799
44. Jahn, H., Wittke, S., Zürbig, P., Raedler, T. J., Arlt, S., Kellmann, M., et al. (2011). Peptide fingerprinting of Alzheimer's disease in cerebrospinal fluid: identification and prospective evaluation of new synaptic biomarkers. PLoS ONE 6:e26540. doi:10.1371/journal.pone.0026540
45. Jawhar, S., Trawicka, A., Jenneckens, C., Bayer, T. A., and Wirths, O. (2010). Motor deficits, neuron loss, and reduced anxiety coinciding with axonal degeneration and intraneuronal Abeta aggregation in the 5XFAD mouse model of Alzheimer's disease. Neurobiol. Aging 33, .e29-.e40. doi:10.1016/j.neurobiolaging.2010.05.027
46. Jawhar, S., Wirths, O., and Bayer, T. A. (2011). Pyroglutamate amyloid-ß (Aß): a hatchet man in Alzheimer disease. J. Biol. Chem. 286, 38825-38832. doi:10.1074/jbc.R111.288308
47. Jin, K., Peel, A. L., Mao, X. O., Xie, L., Cottrell, B. A., Henshall, D. C., et al. (2004). Increased hippocampal neurogenesis in Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 101, 343-347. doi:10.1073/pnas.2634794100
48. Kalinin, S., Richardson, J. C., and Feinstein, D. L. (2009). A PPARdelta agonist reduces amyloid burden and brain inflammation in a transgenic mouse model of Alzheimer's disease. Curr. Alzheimer Res. 6, 431-437. doi:10.2174/156720509789207949
49. Kanekiyo, T., Cirrito, J. R., Liu, C.-C., Shinohara, M., Li, J., Schuler, D. R., et al. (2013). Neuronal clearance of amyloid-ß by endocytic receptor LRP1. J. Neurosci. 33, 19276-19283. doi:10.1523/JNEUROSCI.3487-13.2013
50. Kerimoglu, C., Agis-Balboa, R. C., Kranz, A., Stilling, R., Bahari-Javan, S., Benito-Garagorri, E., et al. (2013). Histone-methyltransferase MLL2 (KMT2B) is required for memory formation in mice. J. Neurosci. 33, 3452-3464. doi:10.1523/JNEUROSCI.3356-12.2013
51. Kishimoto, Y., Higashihara, E., Fukuta, A., Nagao, A., and Kirino, Y. (2013). Early impairment in a water-finding test in a longitudinal study of the Tg2576 mouse model of Alzheimer's disease. Brain Res. 1491, 117-126. doi:10.1016/j.brainres.2012.10.066
52. Klein, W. L. (2002). Abeta toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem. Int. 41, 345-352. doi:10.1016/S0197-0186(02)00050-5
53. Ko, H. S., Uehara, T., Tsuruma, K., and Nomura, Y. (2004). Ubiquilin interacts with ubiquitylated proteins and proteasome through its ubiquitin-associated and ubiquitin-like domains. FEBS Lett. 566, 110-114. doi:10.1016/j.febslet.2004.04.031
54. Kondo, M., Takei, Y., and Hirokawa, N. (2012). Motor protein KIF1A is essential for hippocampal synaptogenesis and learning enhancement in an enriched environment. Neuron 73, 743-757. doi:10.1016/j.neuron.2011.12.020
55. Lambert, J.-C., Heath, S., Even, G., Campion, D., Sleegers, K., Hiltunen, M., et al. (2009). Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat. Genet. 41, 1094-1099. doi:10.1038/ng.439
56. Lambert, J.-C., Ibrahim-Verbaas, C. A., Harold, D., Naj, A. C., Sims, R., Bellenguez, C., et al. (2013). Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat. Genet. 45, 1452-1458. doi:10.1038/ng.2802
57. Leskovjan, A. C., Kretlow, A., Lanzirotti, A., Barrea, R., Vogt, S., and Miller, L. M. (2011). Increased brain iron coincides with early plaque formation in a mouse model of Alzheimer's disease. Neuroimage 55, 32-38. doi:10.1016/j.neuroimage.2010.11.073
58. Lesné, S. E., Sherman, M. A., Grant, M., Kuskowski, M., Schneider, J. A., Bennett, D. A., et al. (2013). Brain amyloid-ß oligomers in ageing and Alzheimer's disease. Brain 136, 1383-1398. doi:10.1093/brain/awt062
59. Li, X., and Buxbaum, J. N. (2011). Transthyretin and the brain re-visited: is neuronal synthesis of transthyretin protective in Alzheimer's disease? Mol. Neurodegener. 6, 79. doi:10.1186/1750-1326-6-79
60. Lidström, A. M., Bogdanovic, N., Hesse, C., Volkman, I., Davidsson, P., and Blennow, K. (1998). Clusterin (apolipoprotein J) protein levels are increased in hippocampus and in frontal cortex in Alzheimer's disease. Exp. Neurol. 154, 511-521. doi:10.1006/exnr.1998.6892
61. Lovell, M. A., Robertson, J. D., Teesdale, W. J., Campbell, J. L., and Markesbery, W. R. (1998). Copper, iron and zinc in Alzheimer's disease senile plaques. J. Neurol. Sci. 158, 47-52. doi:10.1016/S0022-510X(98)00092-6
62. Lundberg, E., Fagerberg, L., Klevebring, D., Matic, I., Geiger, T., Cox, J., et al. (2010). Defining the transcriptome and proteome in three functionally different human cell lines. Mol. Syst. Biol. 6, 450. doi:10.1038/msb.2010.106
63. Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., and Beyreuther, K. (1985). Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. U.S.A. 82, 4245-4249. doi:10.1073/pnas.82.12.4245
64. McLean, C. A., Cherny, R. A., Fraser, F. W., Fuller, S. J., Smith, M. J., Beyreuther, K., et al. (1999). Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 46, 860-866. doi:10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M
65. Medway, C., and Morgan, K. (2014). Review: the genetics of Alzheimer's disease; putting flesh on the bones. Neuropathol. Appl. Neurobiol. 40, 97-105. doi:10.1111/nan.12101
66. Miller, D. L., Papayannopoulos, I. A., Styles, J., Bobin, S. A., Lin, Y. Y., Biemann, K., et al. (1993). Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease. Arch. Biochem. Biophys. 301, 41-52. doi:10.1006/abbi.1993.1112
67. Miners, J. S., Baig, S., Tayler, H., Kehoe, P. G., and Love, S. (2009). Neprilysin and insulin-degrading enzyme levels are increased in Alzheimer disease in relation to disease severity. J. Neuropathol. Exp. Neurol. 68, 902-914. doi:10.1097/NEN.0b013e3181afe475
68. Moechars, D., Dewachter, I., Lorent, K., Reversé, D., Baekelandt, V., Naidu, A., et al. (1999). Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J. Biol. Chem. 274, 6483-6492. doi:10.1074/jbc.274.10.6483
69. Moechars, D., Lorent, K., Strooper, B., Dewachter, I., and van Leuven, F. (1996). Expression in brain of amyloid precursor protein mutated in the alpha-secretase site causes disturbed behavior, neuronal degeneration and premature death in transgenic mice. EMBO J. 15, 1265-1274.
70. Morris, R. (1984). Developments of a water-maze procedure for studying spatial learning in the rat. J. Neurosci. Methods 11, 47-60. doi:10.1016/0165-0270(84)90007-4
71. Nagalakshmi, U., Wang, Z., Waern, K., Shou, C., Raha, D., Gerstein, M., et al. (2008). The transcriptional landscape of the yeast genome defined by RNA sequencing. Science 320, 1344-1349. doi:10.1126/science.1158441
72. Näslund, J., Haroutunian, V., Mohs, R., Davis, K. L., Davies, P., Greengard, P., et al. (2000). Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 283, 1571-1577. doi:10.1001/jama.283.12.1571
73. Nikolic, M., Dudek, H., Kwon, Y. T., Ramos, Y. F., and Tsai, L. H. (1996). The cdk5/p35 kinase is essential for neurite outgrowth during neuronal differentiation. Genes Dev. 10, 816-825. doi:10.1101/gad.10.7.816
74. Nilselid, A.-M., Davidsson, P., Nägga, K., Andreasen, N., Fredman, P., and Blennow, K. (2006). Clusterin in cerebrospinal fluid: analysis of carbohydrates and quantification of native and glycosylated forms. Neurochem. Int. 48, 718-728. doi:10.1016/j.neuint.2005.12.005
75. Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., et al. (2006). Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J. Neurosci. 26, 10129-10140. doi:10.1523/JNEUROSCI.1202-06.2006
76. Ohno, M. (2009). Failures to reconsolidate memory in a mouse model of Alzheimer's disease. Neurobiol. Learn. Mem. 92, 455-459. doi:10.1016/j.nlm.2009.05.001
77. Pfaffl, M. W., Horgan, G. W., and Dempfle, L. (2002). Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res. 30, e36. doi:10.1093/nar/30.9.e36
78. Pham, E., Crews, L., Ubhi, K., Hansen, L., Adame, A., Cartier, A., et al. (2010). Progressive accumulation of amyloid-beta oligomers in Alzheimer's disease and in amyloid precursor protein transgenic mice is accompanied by selective alterations in synaptic scaffold proteins. FEBS J. 277, 3051-3067. doi:10.1111/j.1742-4658.2010.07719.x
79. Phillips, R. G., and LeDoux, J. E. (1992). Differential contribution of amygdala and hippocampus to cued and contextual fear conditioning. Behav. Neurosci. 106, 274-285. doi:10.1037/0735-7044.106.2.274
80. Portelius, E., Bogdanovic, N., Gustavsson, M. K., Volkmann, I., Brinkmalm, G., Zetterberg, H., et al. (2010). Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer's disease. Acta Neuropathol. 120, 185-193. doi:10.1007/s00401-010-0690-1
81. Prelli, F., Castaño, E., Glenner, G. G., and Frangione, B. (1988). Differences between vascular and plaque core amyloid in Alzheimer's disease. J. Neurochem. 51, 648-651. doi:10.1111/j.1471-4159.1988.tb01087.x
82. Price, J. L., and Morris, J. C. (1999). Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann. Neurol. 45, 358-368. doi:10.1002/1531-8249(199903)45:3<358::AID-ANA12>3.0.CO;2-X
83. Qin, S., Hu, X.-Y., Xu, H., and Zhou, J.-N. (2004). Regional alteration of synapsin I in the hippocampal formation of Alzheimer's disease patients. Acta Neuropathol. 107, 209-215. doi:10.1007/s00401-003-0800-4
84. Rademakers, R., Sleegers, K., Theuns, J., van den Broeck, M., Bel Kacem, S., Nilsson, L.-G., et al. (2005). Association of cyclin-dependent kinase 5 and neuronal activators p35 and p39 complex in early-onsetalzheimer's disease. Neurobiol. Aging 26, 1145-1151. doi:10.1016/j.neurobiolaging.2004.10.003
85. Risso, D., Schwartz, K., Sherlock, G., and Dudoit, S. (2011). GC-content normalization for RNA-Seq data. BMC Bioinformatics 12:480. doi:10.1186/1471-2105-12-480
86. Roberts, B. R., Ryan, T. M., Bush, A. I., Masters, C. L., and Duce, J. A. (2012). The role of metallobiology and amyloid-ß peptides in Alzheimer's disease. J. Neurochem. 120(Suppl. 1), 149-166. doi:10.1111/j.1471-4159.2011.07500.x
87. Rogers, J., Cooper, N. R., Webster, S., Schultz, J., McGeer, P. L., Styren, S. D., et al. (1992). Complement activation by beta-amyloid in Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 89, 10016-10020. doi:10.1073/pnas.89.21.10016
88. Roychaudhuri, R., Yang, M., Hoshi, M. M., and Teplow, D. B. (2009). Amyloid beta-protein assembly and Alzheimer disease. J. Biol. Chem. 284, 4749-4753. doi:10.1074/jbc.R800036200
89. Schmitz, C., Rutten, B. P. F., Pielen, A., Schäfer, S., Wirths, O., Tremp, G., et al. (2004). Hippocampal neuron loss exceeds amyloid plaque load in a transgenic mouse model of Alzheimer's disease. Am. J. Pathol. 164, 1495-1502. doi:10.1016/S0002-9440(10)63235-X
90. Schuur, M., Ikram, M. A., van Swieten, J. C., Isaacs, A., Vergeer-Drop, J. M., Hofman, A., et al. (2011). Cathepsin D gene and the risk of Alzheimer's disease: a population-based study and meta-analysis. Neurobiol. Aging 32, 1607-1614. doi:10.1016/j.neurobiolaging.2009.10.011
91. Selkoe, D. J. (1998). The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease. Trends Cell Biol. 8, 447-453. doi:10.1016/S0962-8924(98)01363-4
92. Selkoe, D. J. (2011). Resolving controversies on the path to Alzheimer's therapeutics. Nat. Med. 17, 1060-1065. doi:10.1038/nm.2460
93. Selwood, S. P., Parvathy, S., Cordell, B., Ryan, H. S., Oshidari, F., Vincent, V., et al. (2009). Gene expression profile of the PDAPP mouse model for Alzheimer's disease with and without apolipoprotein E. Neurobiol. Aging 30, 574-590. doi:10.1016/j.neurobiolaging.2007.08.006
94. Shen, Y., Lue, L., Yang, L., Roher, A., Kuo, Y., Strohmeyer, R., et al. (2001). Complement activation by neurofibrillary tangles in Alzheimer's disease. Neurosci. Lett. 305, 165-168. doi:10.1016/S0304-3940(01)01842-0
95. Shukla, V., Skuntz, S., and Pant, H. C. (2012). Deregulated Cdk5 activity is involved in inducing Alzheimer's disease. Arch. Med. Res. 43, 655-662. doi:10.1016/j.arcmed.2012.10.015
96. Snyder, S. E., and Salton, S. R. (1998). Expression of VGF mRNA in the adult rat central nervous system. J. Comp. Neurol. 394, 91-105. doi:10.1002/(SICI)1096-9861(19980427)394:1<91::AID-CNE7>3.3.CO;2-B
97. Stein, T. D., and Johnson, J. A. (2002). Lack of neurodegeneration in transgenic mice overexpressing mutant amyloid precursor protein is associated with increased levels of transthyretin and the activation of cell survival pathways. J. Neurosci. 22, 7380-7388.
98. Stover, K. R., and Brown, R. E. (2012). Age-related changes in visual acuity, learning and memory in the APPswe/PS1dE9 mouse model of Alzheimer's disease. Behav. Brain Res. 231, 75-85. doi:10.1016/j.bbr.2012.02.044
99. Südhof, T. C. (1990). The structure of the human synapsin I gene and protein. J. Biol. Chem. 265, 7849-7852.
100. Sultan, M., Schulz, M. H., Richard, H., Magen, A., Klingenhoff, A., Scherf, M., et al. (2008). A global view of gene activity and alternative splicing by deep sequencing of the human transcriptome. Science 321, 956-960. doi:10.1126/science.1160342
101. Sutherland, G. T., Janitz, M., and Kril, J. J. (2011). Understanding the pathogenesis of Alzheimer's disease: will RNA-Seq realize the promise of transcriptomics? J. Neurochem. 116, 937-946. doi:10.1111/j.1471-4159.2010.07157.x
102. Takemura, R., Nakata, T., Okada, Y., Yamazaki, H., Zhang, Z., and Hirokawa, N. (1996). mRNA expression of KIF1A, KIF1B, KIF2, KIF3A, KIF3B, KIF4, KIF5, and cytoplasmic dynein during axonal regeneration. J. Neurosci. 16, 31-35.
103. Tan, T. C., Valova, V. A., Malladi, C. S., Graham, M. E., Berven, L. A., Jupp, O. J., et al. (2003). Cdk5 is essential for synaptic vesicle endocytosis. Nat. Cell Biol. 5, 701-710. doi:10.1038/ncb1020
104. Thakker-Varia, S., and Alder, J. (2009). Neuropeptides in depression: role of VGF. Behav. Brain Res. 197, 262-278. doi:10.1016/j.bbr.2008.10.006
105. Twine, N. A., Janitz, K., Wilkins, M. R., and Janitz, M. (2011). Whole transcriptome sequencing reveals gene expression and splicing differences in brain regions affected by Alzheimer's disease. PLoS ONE 6:e16266. doi:10.1371/journal.pone.0016266
106. Upadhaya, R. A., Scheibe, F., Kosterin, I., Abramowski, D., Gerth, J., Kumar, S., et al. (2013). The type of Aß-related neuronal degeneration differs between amyloid precursor protein (APP23) and amyloid ß-peptide (APP48) transgenic mice. Acta Neuropathol. Commun. 1, 77. doi:10.1186/2051-5960-1-77
107. van Bakel, H., Nislow, C., Blencowe, B. J., and Hughes, T. R. (2010). Most "dark matter" transcripts are associated with known genes. PLoS Biol. 8:e1000371. doi:10.1371/journal.pbio.1000371
108. van den Pol, A. N., Bina, K., Decavel, C., and Ghosh, P. (1994). VGF expression in the brain. J. Comp. Neurol. 347, 455-469. doi:10.1002/cne.903470311
109. Verwer, R. W. H., Sluiter, A. A., Balesar, R. A., Baayen, J. C., Noske, D. P., Dirven, C. M. F., et al. (2007). Mature astrocytes in the adult human neocortex express the early neuronal marker doublecortin. Brain 130, 3321-3335. doi:10.1093/brain/awm264
110. Vogel, C., and Marcotte, E. M. (2012). Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat. Rev. Genet. 13, 227-232. doi:10.1038/nrg3185
111. Wang, C., Sun, B., Zhou, Y., Grubb, A., and Gan, L. (2012). Cathepsin B degrades amyloid-ß in mice expressing wild-type human amyloid precursor protein. J. Biol. Chem. 287, 39834-39841. doi:10.1074/jbc.M112.371641
112. Wang, Z., Gerstein, M., and Snyder, M. (2009). RNA-Seq: a revolutionary tool for transcriptomics. Nat. Rev. Genet. 10, 57-63. doi:10.1038/nrg2484
113. Watt, N. T., Whitehouse, I. J., and Hooper, N. M. (2010). The role of zinc in Alzheimer's disease. Int. J. Alzheimers Dis. 2011, 971021. doi:10.4061/2011/971021
114. Wirths, O., and Bayer, T. A. (2012). Intraneuronal Aß accumulation and neurodegeneration: lessons from transgenic models. Life Sci. 91, 1148-1152. doi:10.1016/j.lfs.2012.02.001
115. Wirths, O., Multhaup, G., and Bayer, T. A. (2004). A modified beta-amyloid hypothesis: intraneuronal accumulation of the beta-amyloid peptide - the first step of a fatal cascade. J. Neurochem. 91, 513-520. doi:10.1111/j.1471-4159.2004.02737.x
116. Wirz, K. T. S., Bossers, K., Stargardt, A., Kamphuis, W., Swaab, D. F., Hol, E. M., et al. (2013). Cortical beta amyloid protein triggers an immune response, but no synaptic changes in the APPswe/PS1dE9 Alzheimer's disease mouse model. Neurobiol. Aging 34, 1328-1342. doi:10.1016/j.neurobiolaging.2012.11.008
117. Wittnam, J. L., Portelius, E., Zetterberg, H., Gustavsson, M. K., Schilling, S., Koch, B., et al. (2012). Pyroglutamate amyloid ß (Aß) aggravates behavioral deficits in transgenic amyloid mouse model for Alzheimer disease. J. Biol. Chem. 287, 8154-8162. doi:10.1074/jbc.M111.308601
118. Wu, Z.-L., Ciallella, J. R., Flood, D. G., O'Kane, T. M., Bozyczko-Coyne, D., and Savage, M. J. (2006). Comparative analysis of cortical gene expression in mouse models of Alzheimer's disease. Neurobiol. Aging 27, 377-386. doi:10.1016/j.neurobiolaging.2005.02.010
119. Yahata, N., Asai, M., Kitaoka, S., Takahashi, K., Asaka, I., Hioki, H., et al. (2011). Anti-Aß drug screening platform using human iPS cell-derived neurons for the treatment of Alzheimer's disease. PLoS ONE 6:e25788. doi:10.1371/journal.pone.0025788
120. Yu, J.-T., and Tan, L. (2012). The role of clusterin in Alzheimer's disease: pathways, pathogenesis, and therapy. Mol. Neurobiol. 45, 314-326. doi:10.1007/s12035-012-8237-1